Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571375 | 0.81 | MEN1 (0.35) | MEN1KMT2AHASPINMAPK1NTRK1 | |
| SCHEMBL1571542 | 0.74 | ESR2 (0.42) | MEN1KMT2AHASPINNTRK1 | |
| SCHEMBL3046801 | 0.74 | MAPT (0.40) | MEN1KMT2AHASPINNTRK1 | |
| SCHEMBL24924883 | 0.70 | DAO (0.31) | MEN1KMT2A | |
| SCHEMBL24924722 | 0.70 | ALDH1A1 (0.37) | MEN1KMT2A | |
| SCHEMBL3170487 | 0.67 | MEN1 (0.43) | MEN1KMT2AHASPINMAPK1NTRK1 | |
| SCHEMBL14283780 | 0.67 | ALOX15 (0.40) | MEN1KMT2AMAPK1 | |
| SCHEMBL25405416 | 0.67 | ENPP2 (0.39) | MEN1KMT2AHASPINNTRK1 | |
| SCHEMBL17652985 | 0.67 | ALDH1A1 (0.44) | MEN1KMT2AHASPIN | |
| SCHEMBL24253573 | 0.66 | CGAS (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MEN1 1865/4885KMT2A 998/4885HASPIN 496/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | MEN1 1354/4885KMT2A 1065/4885HASPIN 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.